Stocks Health care EDSA
NASDAQ · Health careEdesa Biotech, Inc. (EDSA)
It posted a net loss of $14.1M. At June 30, 2026 it held $10.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Edesa Biotech, Inc. does
Edesa Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EDSA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$7.2M | -$1.27 | n/a |
| 2024 | n/a | -$6.2M | -$1.93 | n/a |
| 2023 | n/a | -$8.4M | -$2.93 | -$6.6M |
| 2022 | n/a | -$17.5M | n/a | -$12.3M |
| 2021 | $0 | -$13.3M | -$1.10 | -$13.7M |
| 2020 | $328.8K | -$6.4M | -$0.74 | -$5M |
Latest SEC filings
What Edesa Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 26, 2026Passive stake (5% or more) SCHEDULE 13G
- August 25, 2026Activist stake changed SCHEDULE 13D/A
- August 25, 2026Activist stake changed SCHEDULE 13D/A
- August 20, 2026
- August 20, 2026
- August 19, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- July 13, 2026
- July 2, 2026
Questions about EDSA
What does Edesa Biotech, Inc. do?
Edesa Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker EDSA.
Is Edesa Biotech, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14.1M.
When did Edesa Biotech, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 1, 2026.
Similar companies
Follow EDSA
Get an email when Edesa Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow EDSA: get an email when it filesWhere the numbers come from
Financial figures are the values Edesa Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.